NOTICE OF ANNUAL GENERAL MEETING IN ILYA PHARMA AB (PUBL) June 26

Presentation of science and an update on the ILP100-development at Broad Institute by MIT and Harvard by Professor Mia Phillipson, May 19th in Boston

This week Professor Mia Phillipson is giving a presentation at the Broad Institute of MIT and Harvard in Boston about her research at Uppsala University in gut barrier, immune cell functions and how they can be targeted at the the Peyers Patches and giving an update on Ilya Pharmas ILP100-Oral program for patients experiencing ICI-induced colitis.

Presentation of results from the SITU-SAFE study at EWMA 2023 in Milan on Friday May 5th

Data is presented by Andreas Fasth, Head of Clinical Development and Medical Affairs who will also participate in the two-day EWMA innovation forum with selected experts and stakeholders.

The value of regulatory interactions developing a new modality in gene therapy- presentation at ISCT Paris May 31 - June 3

Keynote presentation at the National Molecular Medicine Fellows by CEO Evelina Vågesjö

The NMMP program aims to improve scientific networks and collaborations across Sweden, as well as to increase the awareness and accessibility of the cutting-edge infrastructure at SciLifeLab

Ilya Pharma have had a successful preIND meeting with the FDA related to the development of ILP100-Oral

Abstract selected for poster presentation at International Society for Cell- and Gene Therapy 2023 London May 2023

Abstract: The Value of early Regulatory Interactions with Authorities for emilimogene sigulactibac (INN) - a new modality in gene therapy, to be presented by Margareth Jorvid Head of Regulatory Affairs

Ilya Pharma will participate at AMWC 2023 - 21st Aesthetic & Anti-Aging Medicine World Congress

Ilya Pharma is present at the 2023 JPM week in San Francisco 9-13 January

Ilya Pharma will attend Jefferies Health Care Conference in London 15-16 Nov